XTL Biopharmaceuticals Ltd.
Financial ratios & Valuation

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-9.05-4.31-3.39-14.682.97-5.51-25.297.75-2.85-308.8614.102.97
Price/Sales ratio
558.32-3.09K375.30395.60171.07102.09556.4410.05-14.36N/AN/A102.09
Price/Book Value ratio
4.913.803.213.171.061.002.492.761.64247.921.421.06
Price/Cash Flow ratio
-9.26-9.99-4.98-10.19-10.90-7.75-18.32-14.04-7.31-778.50-13.30-7.75
Price/Free Cash Flow ratio
-9.23-9.64-4.80-10.19-10.90-7.74-18.30-14.04-7.31-778.50-13.30-7.74
Price/Earnings Growth ratio
5.02-0.080.070.17-0.000.030.48-0.010.013.11-0.030.03
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
99.95%216.66%86.95%96.55%100%100%96.42%99.93%100.21%N/AN/A100%
Operating Profit Margin
-4931.70%60183.33%-11134.78%-4296.55%-1525%-1220.28%-3385.71%-70.32%191.72%N/AN/A-1525%
Pretax Profit Margin
-5168.29%60366.66%-11065.21%-2693.10%5742.30%-1952.17%-2792.85%29.67%293.68%N/AN/A-1952.17%
Net Profit Margin
-6163.41%71850%-11065.21%-2693.10%5742.30%-1852.17%-2200%129.67%503.05%N/AN/A-1852.17%
Effective Tax Rate
-23.83%-63.88%-32.69%58.51%-255.79%5.12%21.22%-337.01%-71.29%N/AN/A-255.79%
Return on Assets
-44.77%-80.98%-84.35%-11.85%34.82%-17.72%-9.47%28.72%-55.16%-73.45%9.78%-17.72%
Return On Equity
-54.22%-88.21%-94.71%-21.58%35.88%-18.30%-9.85%35.64%-57.73%-80.27%10.23%-18.30%
Return on Capital Employed
-43.21%-73.88%-95.31%-19.82%-9.52%-12.06%-15.17%-16.14%-22.00%-34.45%-23.90%-12.06%
Liquidity Ratios
Current Ratio
3.239.788.3420.6832.3929.4324.09N/AN/AN/A29.5229.43
Quick Ratio
3.049.727.9520.4032.4729.4324.092720.359.9328.6729.43
Cash ratio
2.238.756.1110.9612.8619.2014.2912.8511.196.8014.5412.86
Days of Sales Outstanding
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Days of Inventory outstanding
3.95M1.25K15.81K31.02KN/AN/AN/AN/AN/AN/AN/AN/A
Operating Cycle
3.95M1.25K15.81K31.02KN/AN/AN/AN/AN/AN/AN/AN/A
Days of Payables Outstanding
4.65M6.15K2.06K1.46KN/AN/A730730730N/AN/AN/A
Cash Conversion Cycle
-708.52K-4.90K13.74K29.56KN/AN/A-730-730-730N/AN/AN/A
Debt Ratios
Debt Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.03N/A
Debt Equity Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.03N/A
Long-term Debt to Capitalization
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Total Debt to Capitalization
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Interest Coverage Ratio
N/AN/AN/AN/AN/A-29.03N/AN/AN/AN/A-47.25-29.03
Cash Flow to Debt Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Company Equity Multiplier
1.211.081.121.811.031.031.041.241.041.091.031.03
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
-60.24310.16-75.30-38.79-15.69-13.15-30.35-0.711.96N/AN/A-15.69
Free Cash Flow / Operating Cash Flow Ratio
1.001.031.03111.001.0011111.00
Cash Flow Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Short Term Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A